19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Women's Health
Resources
Basic InformationLatest News
Why So Many Older Women Develop UTIsAHA News: Stress From Work, Home Can Harm Women's HeartsBreastfeeding Brings a Heart Bonus for MomLow-Fat Diet Could Be a Weapon Against Breast CancerAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Routine Use of Antibiotics May Help After Complicated Vaginal Birth: StudyAre You Running Short on Iron?Weight Before Pregnancy Most Important to Risk for ComplicationsIs AI a New Weapon in Breast Cancer Detection?Many Pregnancy-Related Maternal Deaths Occur Months After Delivery: CDCQuitting Smoking Helps Shield Women From Bladder Cancer: StudyThe Surprising Lead Cause of Death for Pregnant WomenBreast Surgeons' Group Issues New Mammogram GuidelinesHow to Know If Your PMS Is Something More SeriousHealth Tip: What to Expect From a Gynecologist VisitMale-Hormone Gene May Help Cause Polycystic Ovary SyndromeWhat Price Beauty for Women? Far More Than for MenSnoring Not Just a Male ProblemMany Women With Heart Disease Falling Short on ExerciseMost States Restrict Pregnant Women's Advance Directives: StudyStudy Supports Radiation for Early, Hormone-Driven Breast CancerLong-Term Antibiotic Use May Up Women's Odds for Heart Trouble1 in 9 U.S. Women Drink During Pregnancy, and Numbers Are RisingNot All Cervical Cancer Rates Are DecliningHPV Vaccine Driving Down Cervical Pre-Cancer RatesAHA News: Here's How Middle-Aged People -- Especially Women -- Can Avoid a Heart AttackC-Section Infection Risk Higher for Moms on Medicaid: StudyLegacy of Gulf War Deployment: Higher Risk of Minor Birth DefectsFDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in WomenCelebrity 'Fat-Shaming' Affects All Women, Study FindsFDA Orders Label Warning on Alcohol Use With 'Female Viagra'Could Very Low 'Bad' Cholesterol Bring Stroke Danger?Herbals in Pregnancy May Endanger Mom, BabyEvenity Approved for Osteoporotic WomenWhen Do Women Need a Mammogram? New Guideline Tries to ClarifyMore Evidence HPV Vaccine Cuts Cervical Cancer RateBlack Women in the U.S. Still Missing Out on Heart CareIs That Medication Safe When Breastfeeding?Birth Control Pills May Protect Against Most Serious Ovarian Cancer: StudySurgery May Boost Outcomes in Common Form of Advanced Breast CancerHealth Tip: Treating EndometriosisFewer Periods May Mean Higher Dementia RiskDual-Drug Therapy May Boost Odds Against a Tough Breast CancerFDA Says Breast Density Must Be Reported to Women During MammogramsAHA News: Stressful Life Events Tied to Heart Disease in Older Black WomenLess Invasive Fibroid Treatment May Work as Well as SurgeryAffordable Care Act Brought Big Benefits to Women: StudyIs There a Safer Choice Than Opioids After a C-Section?Three Clues to Raised Risk of MiscarriageFDA Approves First Drug for Postpartum Depression
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Scientists Spot Clues to Predicting Breast Cancer's Return

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Mar 13th 2019

new article illustration

WEDNESDAY, March 13, 2019 (HealthDay News) -- Figuring out which breast cancer patients will live disease-free after treatment is a bit of a guessing game. But new research indicates breast cancer cells hold molecular clues that may allow doctors to predict who is at high risk of having a recurrence up to 20 years later.

It has long been known that women who are successfully treated for breast cancer can still face a substantial risk of a recurrence years later. But there's no way to zero in on which women are at high risk, and which are unlikely to see the cancer come back.

Right now, doctors can look at certain factors to get a handle on a woman's recurrence risk, said Christina Curtis, one of the senior researchers on the new study.

Women with breast cancer that is ER-positive, for example, have higher odds of a recurrence years after being treated. (That means the cancer's growth is fueled by estrogen.) The same is true of cancer that has spread to multiple lymph nodes by the time it's diagnosed.

But those details don't tell the whole story, said Curtis, an assistant professor of medicine and genetics at Stanford University.

"Unfortunately, [current methods] are not as precise as we'd like them to be," she said. "There's a huge unmet need."

So for their study, Curtis and her colleagues looked to the medical histories of more than 3,000 women diagnosed with breast cancer as far back as 1977. For almost 2,000 of those patients, the researchers were able to dig into the molecular details of their cancer -- including the level of activity in certain cancer-linked genes, and the presence of particular genetic mutations.

When the investigators pulled that information together, they saw that certain subgroups of women faced a high risk of recurrence over the long term.

That included one-quarter of women whose original cancer was ER-positive but negative for the protein HER2 -- a common scenario in breast cancer.

For that one-quarter, the odds of a recurrence over the next 20 years ranged between 42 percent and 55 percent, the findings showed.

Similarly, a portion of women with "triple-negative" breast cancer remained at high risk of recurrence over 20 years. Triple-negative cancer has no receptors for estrogen, HER2 or the hormone progesterone -- and most recurrences happen within the first five years.

Dr. Harold Burstein is a medical oncologist at Dana-Farber Cancer Institute in Boston. He said the new findings could "open a door" toward better-tailoring patients' treatment.

"This study points the way toward understanding, with far more detail, what patients can expect as far as their risk of recurrence," said Burstein, who was not involved in the study.

He cautioned, however, that this is not something patients can ask their doctors about tomorrow. More research is needed before the findings can be translated into a test for use in everyday practice, Burstein said.

The hope, Curtis said, is that when patients are diagnosed with breast cancer, doctors will be able to analyze their tumor for molecular red flags -- and then "stratify them upfront."

If a woman has a cancer that's likely to come back down the road, that might change her treatment.

Burstein pointed to an example: Hormone therapy, with drugs that block estrogen's effects, is a standard treatment for ER-positive cancer. But, he said, there's "controversy" over how long that treatment should last.

If doctors could better predict which patients had a high recurrence risk, those women might want to continue hormone therapy past the standard five years.

At this point, though, it's not known whether such a treatment tactic would change the long-term outlook for those patients, said Dr. George Plitas, a breast cancer surgeon at Memorial Sloan Kettering Cancer Center in New York City.

"How would this be incorporated into clinical practice? It's unclear right now," Plitas said.

That said, he pointed to another contribution of the new findings. They give insight into the biology that helps determine whether a woman will have a recurrence years later. And that could help researchers develop new treatment approaches for those patients.

"This identifies potential molecular pathways for intervention," said Plitas, who played no role in the research.

"I tell my patients that we live in amazing times," he noted. "And this study highlights the fact that [treatment] is going to keep getting better."

The findings were published online March 13 in Nature.

More information

The American Cancer Society has more on breast cancer recurrence.